ghk-cu copper overload wilson's disease Prion protein promotes copper toxicity

However, certain individuals cannot absorb enough through diet alone, even with adequate intake

This content is for informational purposes only and is not a substitute for professional medical advice

The combination has one preclinical synergy paper but no human trial data of its own

When I would show up on the set of news radio, it's like at any moment in time, they're going to figure out that I'm not supposed to be here

Triple-hormone-receptor agonist Retatrutide for obesity: Phase 2 trial (48-week study, up to 24% weight loss) American Diabetes Association (2023) ADA Press Release: Novel agent Retatrutide results in substantial weight reduction (83rd Scientific Sessions, Phase 2 data) ADA Meeting News (2023) Phase 2 trial results: benefits of Retatrutide in obesity, type 2 diabetes, NASH (83rd ADA Scientific Sessions coverage) ClinicalTrials.gov Study of Retatrutide (LY3437943) in adults with obesity (NCT04881760